Genomics Clinical Trials Centre

Genomics Clinical Trials Centre   –   OPEN DAY 2017

On Friday 25th August 2017 the GCT Centre will open its doors to the public to raise awareness about Alzheimer’s disease. If you or someone you know would be interested in learning about this disease or would be interested in participating in research on Alzheimer’s disease, please come along to our Open Day.

Details:

Venue: The Genomics Clinical Trials Centre, Queensland University of Technology

 Address: 299 Rio Vista Boulevard, Mermaid Waters 4218

Date: Friday 25 August 2017

Time: the clinic will be open to the public any time between 11:30am-4pm

Contact number: 07 5688 7170.

 

We hope to see you there!

 


About

 

The Genomics Clinical Trials Centre is a facility dedicated to conducting new treatment clinical
trials, situated in the centre of the Gold Coast at Mermaid Waters. The GCT Centre consists of a multi-disciplinary team actively involved in study design, recruitment, database creation and management, biostatistical analysis and reporting for research studies in Alzheimer’s disease, migraine, hypertension, breast, skin and prostate cancer, osteoporosis and multiple sclerosis.

At present, there are 4 concurrent studies into Alzheimer’s disease, each taking a slightly different approach to unlocking this debilitating condition. These studies are made possible by the contribution of the Gold Coast community whose seniors volunteer their time and effort toward these important trials. If you or someone you know is interested in participating in these studies, please contact our clinic for more information and see the below information on our current studies.

 

Current Studies

 

The Early Study – currently recruiting

The EARLY clinical trial is researching the safety and effectiveness of an investigational medicine that may help to delay memory loss associated with Alzheimer’s disease. The investigational medicine developed by Janssen Research and Development is designed to prevent the production of amyloid beta fragments in the brain. Amyloid beta (which is a protein) is found at high levels in the brains of people with Alzheimer’s disease and is believed to be one of the key features of the progression of the disease.  This investigational medicine aims to reduce the formation of these amyloid beta fragments, which is thought to slow down or prevent the cognitive and functional decline associated with Alzheimer’s disease. This trial will last for about 5 years and will involve regular visits to the trial centre. We are currently looking for people who do not have any symptoms but are worried that they may develop Alzheimer’s in the future.

Are you able to help?

You (or someone you know) may be able to take part in the EARLY Trial if :

  • Are 60-85 years of age
  • If you are age 60 to 64, you will need to have at least one of the following:
    • a parent or sibling with Alzheimer’s disease
    • been told you are at risk of developing Alzheimer’s disease (that you have the APOE ε4 gene or a proven build- up of amyloid in your brain)
  • Have normal memory and thinking abilities
  • Even if you are worried you have subtle memory changes, you may still be able to take part. The trial doctor will work with you to determine if this trial is right for you.
  • Have a close friend, relative or spouse who can come to some trial visits with you.

The Engage Study – currently recruiting

The ENGAGE study is investigating whether Aducanumab has the potential to be a safe and helpful treatment that slows down disease progression in people with early Alzheimer’s disease. Aducanumab is a drug that has already had some limited testing in humans for safety and effectiveness. It is now being tested further in a larger number of people. There is a substance called amyloid beta (which is a protein) found at high levels in the brains of people with Alzheimer’s disease which is believed to be one of the key features of the progression of the disease. Aducanumab binds amyloid beta and removes existing deposits and stops new deposits from forming. The ENGAGE study will last for around 4 years in total and consists of two treatment phases – an initial 18 month treatment period which has a placebo group and an optional 2- year long term extension phase of the study.

Are you able to help?

You (or someone you know) may be able to take part in THE ENGAGE study if you:

  • Are 50-85 years of age
  • Are in good health (apart from early Alzheimer’s disease)
  • Have a study partner who, for the duration of the study, is able to provide accurate information on the participant’s cognitive and functional abilities, and attend at least nine specific clinic visits over the duration of the study.

The TOMMORROW Study (301 & 303) – recruiting ended

The TOMMORROW study is a research study seeking to learn more about the earliest stages of Alzheimer’s disease. It seeks to understand the genetic risk factors of developing Mild Cognitive Impairment (MCI) due to Alzheimer’s disease using a genetic blood test. This study will evaluate whether a new investigational test involving two specific genes (APOE gene and the TOMM40 gene) that have been previously shown to increase the risk of developing Alzheimer’s disease, can predict a person’s risk for developing mild cognitive impairment in the next 5 years. A second goal is to explore whether an investigational medication will delay the first symptoms of MCI due to AD in people who are cognitively normal. This study is a global phase 3 trial that has recruited more than 5,000 healthy senior participants in approximately 50 study centres worldwide.


 

If you would like to participate in one of our clinical trials being run on the Gold Coast, please contact our centre at Mermaid Waters:

Email: gctcentre(@)qut.edu.au – please note, you will need to remove the brackets.

Phone: 07 5688 7170